

# Special Issue

## Immunogenomics in Cancer

### Message from the Guest Editor

The immune system can recognize and attempt to reject cancer cells as foreign; however, cancer cells can develop ways to evade immune surveillance.

Neoantigens, which are defined as highly cancer-specific proteins, generated from somatic mutations in individual patients, play pivotal roles in the development of anti-cancer immunity.

Immunogenomics stands at the forefront of today's research against cancer. The field itself combines immunology and genomics. More specifically, it includes the identification and analysis of genetic variations, mutations, and alterations in both cancer cells and the immune system.

Today, novel technologies and disciplines including next generation sequencing and computational biology allow for more effective study of immune response genetics against neoantigens and therapeutic regimes.

The aim of this Special Issue is to shed light on the genetics and genomics of the immune response against cancer. Novel research articles, letters, and review papers are welcome in order to form a collection of significant research items that promote the subject of immunogenomics in cancer.

---

### Guest Editor

Dr. Nikos G. Gavalas

1. Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 80 Vas. Sofias Avenue, 11528 Athens, Greece

2. 2nd Propaedeutic Department of Medicine, Attikon University Hospital, 1 Rimini St., Chaidari, 124 62 Athens, Greece

---

### Deadline for manuscript submissions

closed (5 April 2025)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/202190](https://mdpi.com/si/202190)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))